Short answer
TG THERAPEUTICS, INC. (TGTX) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $205M (up 69.6% year over year) with net income of $20M.
Q1 2026 key financials · XBRL
- Revenue
- $205M
- +69.6% YoY
- Net income
- $20M
- +290.8% YoY
- Operating margin
- 17.0%
- EPS (diluted)
- $0.12
- +300.0% YoY
Source: XBRL data from the TG THERAPEUTICS, INC. (TGTX) Q1 2026 10-Q on SEC EDGAR. USD.
TG THERAPEUTICS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $204.9M, up $84.1M YoY from $120.9M
- Product revenue $201.3M, led by U.S. BRIUMVI $194.8M vs $119.7M
- Net income $19.8M vs $5.1M YoY; net margin 9.7% vs 4.2%
- Cash, equivalents and investment securities $572.8M at March 31, 2026
- $500M net non-dilutive financing; share repurchases $100M during Q1 2026
Risk Factors
- BRIUMVI market-acceptance risk, with only one marketed product and limited commercialization experience
- Post-marketing compliance risk, including FDA-required long-term safety, pregnancy, and pediatric studies
- Emerging safety risk, as longer-term and broader BRIUMVI exposure may reveal unexpected adverse events
- Competitive risk, with larger biopharmaceutical companies possessing greater development, commercialization, and capital resources
- Pricing risk, as ex-U.S. partner pricing could influence U.S. reimbursement under most-favored-nation proposals
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TG THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.